Welcome to the
European Biotechnology Network!
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.
The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.
Catch of the day
Roche licences DARPins05.12.2013 Roche and Molecular Partners team up in a CHF1bn deal to develop a novel class of anti-cancer conjugates.Catch of the Day is brought to you by European Biotechnology News
Roche aims to join its toxic payload portfolio to antibody-like small molecules dubbed DARPins, developed by Molecular Partners. According to Roche, the DARPin-drug conjugates offer the potential of enhanced efficacy with substantial patient benefit over existing therapies. Additionally, they target other cancer protein epitopes thus complementing Roche's antibody drug conjugates (ADCs) portfolio. Roche has licensed cancer-killing warheads from Immunogen Inc., Spirogen, and Wilex subsidiary Heidelberg Pharma for use in ADCs.
Under the terms of the agreement, Roche has rights to develop and commercialise several DARPin-based products. Molecular Partners is entitled to receive upfront and initiation payments up to CHF55m. Furthermore, Molecular Partners will receive research funding and could earn more than CHF1bn if all development and sales milestones are met for all potential products. In addition, Molecular Partners will receive tiered royalties into the double-digit percentage on any future product range sales.
DARPins are non-antibody-based small proteins, where a variable region has been engineered for target binding. Their small size and high binding affinity enable them to hone in on and penetrate deep into solid tumours. DARPins are thus ideal targeting agents to deliver toxic agents to tumours to kill cancer cells. As a result of their ability to bind to different epitopes than antibodies, and by binding to multiple epitopes or targets in parallel at the same time, DARPins are believed to have a higher selectivity for tumour cells compared to other biologics including antibody drug conjugates.
Our Corporate Members are
European Biotechnology Network
Avenue de Tervueren 13
1040 Brussels, Belgium
Tel: +32 27 33 72 37